PT -期刊文章AU - d Knopman AU - l .施耐德AU - k·戴维斯盟- s Talwalker AU - f·史密斯AU - t·胡佛AU - s Gracon TI -长期他克林(Cognex)治疗援助- 10.1212 / WNL.47.1.166 DP - 1996年7月01 TA -神经病学第六PG - 166 - 177 - 47 IP - 1 4099 - //www.ez-admanager.com/co首页ntent/47/1/166.short 4100 - //www.ez-admanager.com/content/47/1/166.full所以Neurology1996 7月01;47 AB -目的:评估可能的联系他克林(Cognex,莫里斯Parke-Davis制造,平原,NJ)剂量和疗养院安置的可能性(额定马力)或死亡患者的广告。设计:一个报告显示,随机、双盲、安慰剂对照,与这些相应平行的组织多中心临床试验,涉及663名患者,公开之后,患者治疗和随访2年以上。患者:在基线,门诊病人至少50年的年龄,遇到标准可能的广告,与细微精神状态检查基准分数10至26(包容),健康,有一位照顾者可以提供评估和确保服药情况。干预措施:随机分配安慰剂或三升剂量方案之一他克林在30周,紧随其后的是开放标签治疗所有患者开始双盲试验。结果措施:使用逻辑回归进行额定马力和死亡。Results: Patients who remained on tacrine and were receiving doses > 80 mg/d or > 120 mg/d were less likely to have entered a nursing home than patients on lower doses (odds ratios > 2.7, 2.8, respectively.) There was a trend for lower mortality for patients receiving > 120 mg/d (p = 0.063). Conclusions: Treatment with tacrine at doses > 80 mg/d was associated with a reduced likelihood of NHP. These data demonstrate that tacrine's 30-week effects on cognitive function and clinicians' global ratings may generalize to effects on a major milestone of AD. Future studies should attempt to replicate these findings prospectively. NEUROLOGY 1996;47: 166-177